INTRODUCTION
One of the key functions of the extracellular matrix is the storage and presentation of growth factors to cells. Proteoglycans are important mediators of growth-factor binding, and they have been shown to modulate the biological activities of a variety of growth factors through interaction via their glycosaminoglycan moieties as well as their core proteins (Ruoslahti, 1989; Ruoslahti and Yamaguchi, 1991) .
Growth factors that bind to glycosaminoglycans include acidic and basic fibroblast growth factor (Burgess and Maciag, 1989) , granulocyte-macrophage colony-stimulating factor, interleukin 3 (Roberts et al., 1988) , pleiotrophin (Li et al., 1990) , amphiregulin (Shoyab et al., 1988) , heparin-binding epidermal growth factor (EGF) (Higashiyama et al., 1991) and platelet factor 4 (Huang et al., 1982) , each of which binds avidly to heparin and heparan sulphate. The binding of fibroblast growth factors to heparin or heparan sulphate proteoglycans protects the growth factors from proteolytic degradation and is thought to create a matrix-bound growth-factor reservoir (Saksela et al., 1988; Gospodarowicz et al., 1990 ) from which the growth factor can be released in an active form by partial proteolysis of the proteoglycan core protein or through degradation of the heparan proteins; removal of the chondroitin/dermatan sulphate chains of decorin and biglycan (fibromodulin is a keratan sulphate proteoglycan) increased the activities of decorin and biglycan, suggesting that the glycosaminoglycan chains may hinder the interaction of the core proteins with TGF-/J. The 82 and 3 also bound to all three fusion proteins. Latent recombinant TGF-fi1 precursor bound slightly to fibromodulin and not at all to decorin and biglycan. The results show that the three decorintype proteoglycans each bind TGF-, isoforms and that slight differences exist in their binding properties. They may regulate TGF-fl activities by sequestering TGF-fl into extracellular matrix.
sulphate moiety of the proteoglycans (Saksela and Rifkin, 1990; Ishai-Michaeli et al., 1990) . Basic fibroblast growth factor has to be bound to glycosaminoglycan to be able to interact with its signal-transduction receptor (Yayon et al., 1991; Rapraeger et al., 1991) .
The binding of transforming growth factor , (TGF-/?) to proteoglycans represents a different type of growth-factorproteoglycan interaction. TGF-/? has been demonstrated to bind to the core proteins of at least two proteoglycans. One of these proteoglycans is the type-III TGF-,8 receptor, betaglycan (Segarini and Seyedin, 1988; Andres et al., 1989) . Betaglycan is a cell-membrane proteoglycan (L6pez-Casillas et al., 1991 ; Wang et al., 1991) which apparently is not involved in the TGF-/5 signal-transduction pathway but may function as a cell-surface TGF-/J reservoir presenting TGF-/J to its signal-transduction receptors.
The second type of TGF-,f-binding proteoglycan is decorin, a small interstitial extracellular matrix proteoglycan that can interact with TGF-,f via its core protein (Yamaguchi et al., 1990) .
Decorin (Krusius and Ruoslahti, 1986 ) is the prototype of a group of proteoglycans characterized by core proteins of -40 kDa which consist mainly of leucine-rich repeats of 20-24 amino acids (Patthy, 1987 It To whom correspondence should be addressed.
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of proteoglycans have been cloned; in addition to decorin, these are biglycan (Fisher et al., 1989) , fibromodulin (Oldberg et al., 1989) and lumican (Blochberger et al., 1992) . Decorin and biglycan are ubiquitous, although they show a quite divergent localization within tissues, with decorin found more in the extracellular matrix of tissues where it is bound to type-I collagen (Vogel et al., 1984; Scott, 1986; Brown and Vogel, 1989) and biglycan localized more closely around cells (Bianco et al., 1990) . Fibromodulin has a somewhat more restricted distribution with high concentrations in cartilage, tendon and sclera, and low concentrations in skin and mineralized bone (Heinegard et al., 1986) . Lumican is found mainly in the cornea (Blochberger et al., 1992) .
In the present study we have investigated the abilities of recombinant decorin, biglycan and fibromodulin fusion proteins, as well as the corresponding proteoglycans purified from bovine tissues, to interact with TGF-f8. We show that all three proteoglycans interact with the three mammalian isoforms of 8 Simian TGF-,81 and TGF-,81 precursor were purified from culture supernatants of stable Chinese hamster ovary-cell transfectants as described previously (Gentry et al., 1987) . Bovine TGF-p)2 was purified from demineralized bone (Seyedin et al., 1985) . Decorin, biglycan and fibromodulin were purified from bovine tissues as described previously (Heinegard et al., 1985) .
Cloning of human biglycan and fibromodulin cONAs Total cellular RNA was extracted by using guanidinium isothiocyanate (Sambrook et al., 1989 ) from subconfluent cultures of WI-38 human lung fibroblasts that had been exposed to TGF-,f1 (3 ng/ml) for 12 h. Total cellular RNA (1 ,ug) was reverse-transcribed with MoMuLV reverse transcriptase using random hexanucleotides for cDNA priming (Kawasaki, 1989) . Double-stranded cDNAs encoding the full-length coding sequences of human biglycan or human fibromodulin were generated by amplification of the reverse-transcribed WI-38 RNAs using amplimers based on the published sequences of human biglycan (Fisher et al., 1989) or bovine fibromodulin (Oldberg et al., 1989) . The PCR products were subcloned into pBluescript and analysed by DNA sequencing (Sanger et al., 1977) . Our biglycan clone differs from the published biglycan sequence in five bases. Two of these could be reconciled by resequencing of clone p16 of Fisher et al. (1989) 
Construction of expression vector
The pQE-8/MBP expression vector was generated by subcloning a BglII-BamrHI DNA fragment coding for maltose-binding protein (MBP) and a factor Xa protease cleavage site into the BamHI site of pQE-8. BamHI fragments coding for the core proteins of human biglycan, decorin or fibromodulin were subsequently cloned into the resulting single Bam HI site in pQE-8/MBP.
Expression and purification of fusion proteins
Biglycan, decorin and fibromodulin were prepared according to the instructions provided by Qiagen. Briefly, recombinant bacteria were grown in Luria-Bertani medium containing ampicillin (100 jtg/ml) and kanamycin (25 ,ug/ml) at 37°C to a density of A600 0.6-0.8. IPTG was then added to a final concentration of 2 mM and protein expression was allowed to proceed for 3 h. The bacteria were then collected by centrifugation (5000 g, 15 min) and lysed for 45-60 min in buffer A (0.1 M NaHPO4, 0.01 M Tris, 6 M guanidinium chloride, pH 8.0). The lysates were centrifuged for 20 min at 20000 g. Imidazole was added to the supernatants to a final concentration of 10 mM and the mixtures were loaded on Ni-NTA columns (Hochuli et al., 1987) . The columns were washed with several column volumes of buffer B (0.1 M NaHPO4, 0.01 M Tris, 8 M urea, pH 8.0) and eluted with buffer C (buffer B adjusted to pH 5.9). Proteincontaining fractions were adjusted to pH 8 by adding 1 M Tris/HCl in 8 M urea. After reduction of the proteins with dithiothreitol and carboxymethylation with iodoacetamide (Charbonneau, 1989) , they were separated from the reagents and buffers exchanged for the respective binding buffers by gel filtration using PD-10 columns.
iodination of proteins Fusion proteins expressed in bacteria were iodinated using lodogen according to the manufacturer's instructions. Briefly, 50 ,ul of an lodogen solution (1 mg/25 ml of chloroform) was dried to the bottom ofa borosilicate glass tube. Protein (10-20 ,ug) dissolved in iodination buffer (0.1 M NaHPO4, 1 mM EGTA, 150 mM NaCl, pH 7.4) and carrier-free Nal25I were added to the tube. After incubation for 12 min at room temperature, 200 ,u of iodination buffer and the mixture were loaded on to a PD-10 column for radiochemical purification of the labelled protein.
The specific radioactivities and radiochemical purities of the labelled fusion proteins were calculated by determination of the picric acid-precipitable radioactive protein fraction in the labelling mixture before and after the purification step. The specific radioactivities ranged from 2300 to 2800 Ci/mmol, with radiochemical purities greater than 95 %. TGF-,f1, 2 and 3 (1-5 jug)
were labelled as described above using 0.25 M NaHPO4/2 M urea, pH 7.4, as iodination buffer.
Chondroltinase ABC treatment of proteoglycans Enzymic removal of glycosaminoglycan side chains from native biglycan and decorin was performed by treating 0.5 mg/ml proteoglycan with 50 jul of 20 units/ml chondroitinase ABC (Seikagaku 100330; 110 units/mg) in 0.1 M Tris/HCl, pH 8.0, containing 0.03 M sodium acetate for 5 h at 37 'C. The efficiency of the enzyme digestion was confirmed by SDS/PAGE, where samples of treated biglycan and decorin migrated with the expected core protein molecular sizes of about 40 kDa.
Solid-phase binding assays Immulon-2 microtitre wells were coated with TGF-/31 (75 jul, 1 ,ug/ml) or other proteins dissolved in 0.1 M NaHCO3 buffer, pH 9.5, overnight at 4 'C. The coated wells were then flicked dry and incubated with 200,d of binding buffer (50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 20% BSA, 0.050% Tween 20, 0.01 % NaN3) for 3 h at 37 'C to block non-specific binding sites. Plates were either used immediately or stored for future use at -20 'C for up to 2 weeks. For binding assays, the blocked wells were washed once, then labelled, and unlabelled proteins were added in a total volume of 100 jul of binding buffer and incubated for 6 h at 37 'C if not indicated otherwise. Thereafter the well contents were removed by aspiration and the wells were washed three times with ice-cold binding buffer. Binding to the surfaceimmobilized proteins was determined by counting the entire wells in a y counter. Non-specific binding to the wells was less than 5 % of the total radioactivity added. The coating efficiency for TGF-/Jl was 58.7 + 0.5 % (n = 3), giving approximately 44 ng of TGF-fil per well. The coating efficiency was calculated by adding a small amount of '251-labelled TGF-,ll to the coating solution and determining the surface-associated radioactivity after the overnight incubation period and the subsequent washing step. All experiments were performed in duplicate or triplicate.
Analyses of equilibrium binding data Data from equilibrium binding experiments were analysed using the LIGAND computer program (Munson and Rodbard, 1980) on an Apple Macintosh II computer.
Cell-binding experiments Cell-binding experiments were performed as described by Massague (1987 Cross-linking of TGF-pt to receptors For receptor cross-linking, cells were grown in 24-well culture dishes and processed as described above. After incubation with labelled and unlabelled ligands, the cells were washed once with binding buffer and three times with binding buffer without BSA. Then 100 jul of binding buffer (without BSA) containing disuccinimidyl suberate (final concn. 0.2 mM) was added, and the cells were incubated for 15 min at 4 'C. After the crosslinking reaction, the cells were lysed in 100 jul of solubilization buffer (125 mM NaCl, 10 mM Tris/HCl, pH 7, 1 mM EDTA, 1 % Triton X-100, 10 jug/ml leupeptin, 10 jug/ml antipain, 50 mg/ml aprotinin, 100 jug/ml benzamidine hydrochloride, 10 jug/ml pepstatin). The lysates were mixed with sample buffer and analysed by SDS/PAGE under reducing conditions using precast 4-12% Novex gels. After electrophoresis the gels were dried and exposed to XAR-100 X-ray film for several days at 70°C. (Figure 5a ). MBP-decorin and MBP-fibromodulin also competed for the binding of labelled MBP-biglycan to TGF-,81.
RESULTS

Bacterial fusion proteins
They competed about as effectively as MBP-biglycan, yielding half-maximal inhibitory concentrations of about 30-40 nM, whereas MBP alone was inactive. When purified bovine proteo- shown. After incubation for 6 h at 37 0C, the wells were washed three times and counted in a y counter. Binding was corrected for non-specific binding and is expressed as percentage of the total amount of labelled 1251-MBP-biglycan added to the wells.
glycans were used as competitors (Figure 5b ), biglycan and decorin were found to be less potent than fibromodulin; the halfmaximal inhibitory concentrations were 150, 200 and 10 nM respectively. Calculation of dissociation constants from the data shown in Figure 5 to allow any conclusion about the effect of proteoglycan on that receptor.
DISCUSSION
The data presented here extend the previously published findings that decorin can bind TGF-,fl and that biglycan can block that binding (Yamaguchi et al., 1990) . We demonstrate that at least three members of the family of small interstitial decorin-like tissue proteoglycans, decorin, biglycan and fibromodulin, show similar but not identical TGF-,8-binding activities.
Solid-phase radioligand-binding studies demonstrated that recombinant fusion proteins containing the core protein sequences of human biglycan, decorin and fibromodulin compete for binding of labelled MBP-biglycan to TGF-fll with similar affinities, indicating that functionally highly conserved regions of the core proteins are involved in this binding. The fact that bacterially produced recombinant proteoglycan core proteins had similar activities to recombinant decorin produced by mammalian cells (Yamaguchi et al., 1990 ) and tissue-derived proteoglycans definitively established the presence of TGF-flbinding activity in the core proteins of these proteoglycans. It is not yet known which regions of the core protein are involved, but the highest homology scores are found within the leucine-rich repeat regions. As these repeats are thought to represent a general motif for protein-protein interaction (Ruoslahti, 1988) . Affinity labelling ofthe type-I receptor by TGF-, also appeared to be affected by the decorin-type proteoglycans. However, workers in our laboratory have recently identified a 60 kDa TGF-,8-binding protein that is superimposed on the type-I receptor in gel analysis of TGF-/3-affinity-labelled components but that is bound to the cell surface via glycosaminoglycans rather than being a receptor (Biitzow et al., 1993) . The Mv 1 Lu cells used in the assay do not appear to possess significant amounts of the 60 kDa protein (Biitzow et al., 1993) ; nevertheless, the apparent effect of the proteoglycans on the type-I receptor labelling should be interpreted with some caution at this time. The proteoglycans had no detectable effect on the labelling of the type-II signal-transduction receptor, and, because of this, it may be that secondary factors such as matrix binding or internalization of the proteoglycan (Hausser et al., 1989) determine whether or not TGF-fl activity is inhibited. In fact, the experimental conditions used so far may not adequately reflect the situation in vivo; in vivo the proteoglycan-TGF-,8 interaction is unlikely to take place in the fluid phase. It is more likely that TGF-/i would encounter extracellular matrix-associated proteoglycans; decorin and fibromodulin would be associated with type-I collagen in tissues. Although it has not been shown yet that collagen-associated decorin or fibromodulin can interact with TGF-fl, it is possible that proteoglycans bound to the extracellular matrix compete with the receptors by sequestering TGF-,? into the extracellular matrix, away from the receptors. Work is underway to test this hypothesis.
Increased TGF-,l production has been found to be an important element in a number of fibrotic diseases that are characterized by an accumulation of extracellular matrix components . For example, TGF-,J plays a pivotal role in the pathogenesis of experimentally induced glomerulonephritis, the most critical manifestation of which is the accumulation of extracellular matrix in the glomeruli (Border et al., 1990b) . In addition to increasing the synthesis of fibronectin, collagens and tenascin (Ignotz and Massague, 1986; Varga et al., 1987; Pearson et al., 1988) , TGF-fl also up-regulates the expression of proteoglycans (Bassols and Massague, 1988) . In mesangial cells both decorin and biglycan can increase as much as 50-fold after induction by TGF-fl (Border et al., 1990a) , whereas in fibroblasts only biglycan seems to be increased (Romaris et al., 1991; Kahari et al., 1991) . Fibromodulin has not been studied in this regard. A recent study shows that injection of recombinant decorin into glomerulonephritic rats can suppress matrix accumulation . It may be significant that the type-I receptors, which appear to be affected in their TGF-/J binding by the decorin-type proteoglycans, have been found to be responsible for the effects of TGF-,J on matrix accumulation (Arrick et al., 1992; Chen et al., 1993) . Our results suggest that each of the decorin-type proteoglycans may be able to suppress in vivo matrix accumulation and that fibromodulin could be particularly effective in this regard.
